Chronic renal failure future or investigational therapies
Jump to navigation
Jump to search
|
Chronic renal failure Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Chronic renal failure future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Chronic renal failure future or investigational therapies |
|
FDA on Chronic renal failure future or investigational therapies |
|
CDC on Chronic renal failure future or investigational therapies |
|
Chronic renal failure future or investigational therapies in the news |
|
Blogs on Chronic renal failure future or investigational therapies |
|
Risk calculators and risk factors for Chronic renal failure future or investigational therapies |
Emerging Therapies
- Primary, secondary, and tertiary prevention of CKD is increasingly possible because of genetic diagnoses.
- A recent study involving a small molecule Inaxaplin reverses the toxic gain-of-function effect of APOL1 high-risk variants, in patients with two APOL1 variants and biopsy-proven FSGS.
- A mouse model showed that gene transfer of Pkd1 trans gene lead to re expression of polycystic 1 protein thereby markedly delayed cyst development, retarded cyst progression, and postponed kidney failure in Pkd